ID: ALA503209

Max Phase: Preclinical

Molecular Formula: C25H25ClN2O5

Molecular Weight: 468.94

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(Oc2ccc3c(c2)C[C@@H](NC[C@H](O)c2ccc(Cl)nc2)CC3)cc1C(=O)O

Standard InChI:  InChI=1S/C25H25ClN2O5/c1-32-23-8-7-20(12-21(23)25(30)31)33-19-6-3-15-2-5-18(10-17(15)11-19)27-14-22(29)16-4-9-24(26)28-13-16/h3-4,6-9,11-13,18,22,27,29H,2,5,10,14H2,1H3,(H,30,31)/t18-,22-/m0/s1

Standard InChI Key:  MVBZNYMDBPDLIU-AVRDEDQJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 468.94

Molecular Weight (Monoisotopic): 468.1452

AlogP: 4.41

#Rotatable Bonds: 8

Polar Surface Area: 100.91

Molecular Species: ZWITTERION

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.44

CX Basic pKa: 9.57

CX LogP: 1.59

CX LogD: 1.59

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.42

Np Likeness Score: -0.46

References

1. Imanishi M, Nakajima Y, Tomishima Y, Hamashima H, Washizuka K, Sakurai M, Matsui S, Imamura E, Ueshima K, Yamamoto T, Yamamoto N, Ishikawa H, Nakano K, Unami N, Hamada K, Matsumura Y, Takamura F, Hattori K..  (2008)  Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.,  51  (15): [PMID:18651730] [10.1021/jm800222k]

Source

Source(1):

• Scientific Literature